Alexion Pharmaceuticals will keep its New Haven team in place following its merger with drug giant AstraZeneca — at least through the end of 2021, according to a regulatory filing.
“All current Alexion site plans will remain unchanged in 2021,’ according to a transition planning update filed with the U.S. Securities and Exchange Commission on May 6.
“As we move into 2022, you can expect a continued presence in the New Haven site,” the update continued.